Helix and AstraZeneca Sign Multi-Year Genomics Data Partnership

Helix, an enterprise genomics company, has entered a multi-year relationship with AstraZeneca, under which AstraZeneca will gain access to its phenotyped GenoSphere cohorts covering a wide range of disease areas.

Helix’s GenoSphere cohorts consist of comprehensive Exome+ genomic and rich longitudinal clinical data, designed to accelerate Life Sciences research across the development cycle. These de-identified datasets are powered by the Helix Research Network, a large and still-growing precision health network in North America.

Helix’s datasets and network offer key advantages, including genomic data from Exome+ sequencing that provides deep insights into thousands of genes and variants across disease areas; curated, longitudinal clinical data with an average electronic health record (EHR) history of 13 years, including diagnoses, lab results, and regular data refreshes to follow the patient journey; and a fully consented cohort that enables targeted follow-on studies to launch with speed and precision.

“Our collaboration with AstraZeneca highlights how integrated large-scale clinico-genomic data is becoming a foundational resource in advancing biomedical research and therapeutic development,” said James Lu, M.D., Ph.D., CEO and co-founder of Helix. “By combining comprehensive genomic data with rich longitudinal clinical information, we can help accelerate research, generate deeper insights into disease, and advance the development of more targeted medicines.”